Impact of Oral GLP-1s on Food and Beverage Industry Dynamics
The recent approval of orforglipron (Foundayo) by the US Food and Drug Administration marks a significant advancement in GLP-1 weight-loss treatments. This medication is notable for its potential to help users maintain weight loss after transitioning from injectable GLP-1s. Unlike injectables, orforglipron is a pill, offering greater convenience and accessibility.
According to a study sponsored by Eli Lilly, orforglipron can effectively sustain weight loss in individuals who have previously used injectable GLP-1s like semaglutide and tirzepatide. The study, involving 376 patients, demonstrated that those who switched to orforglipron retained a substantial portion of their weight loss compared to a placebo group. Specifically, individuals who had been on tirzepatide maintained 75% of their weight loss, while those on semaglutide retained 79%.
The implications for the food and beverage industry are profound. Experts suggest that companies should not rely on consumers reverting to previous eating habits post-treatment. Instead, there is a need to focus on nourishing products that support the nutritional needs of GLP-1 users. This shift is critical as GLP-1s have been associated with potential deficiencies in micronutrients, protein, and fiber.
Industry Response to Changing Consumer Needs
Industry leaders like Chobani and Nestlé have begun to address these needs. Chobani's high-protein drink portfolio is designed to support digestibility, while Nestlé's Vital Pursuit platform is exploring nutrition support across the treatment journey. Such initiatives reflect a targeted approach to meeting the dietary requirements of GLP-1 users.
Currently, orforglipron is approved for use only in the United States. However, Eli Lilly is seeking approval in more than 40 countries, including the UK and EU nations. This broader approval could further influence the global uptake of GLP-1 medications, as these oral formats offer a more accessible option compared to injectables.
Future Prospects and Considerations
While the study on orforglipron provides promising results, experts caution that more research is needed to fully understand the long-term effects of oral GLP-1s. Nonetheless, the emergence of these medications could redefine consumer behavior and present new opportunities for product innovation in the food and beverage sector.
